<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02636101</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-DAIVOBETGEL-1210</org_study_id>
    <nct_id>NCT02636101</nct_id>
  </id_info>
  <brief_title>Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study</brief_title>
  <acronym>BODYGUARD</acronym>
  <official_title>Xamiol® Gel in BODY Psoriasis : lonG-term Management of Psoriasis vUlgARis With Xamiol® Gel in Daily Clinical Practice of Russian Dermatologists. A Long-term Observational, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to describe the patient population treated and the real-life patients'
      experiences with Xamiol®gel in the long term, up to 52 weeks management of body psoriasis
      vulgaris in Russia. The result will increase the knowledge on Xamiol®gel enabling
      dermatologists and patients to optimize its use in the long term management of psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">February 15, 2018</completion_date>
  <primary_completion_date type="Actual">February 15, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient reported treatment satisfaction</measure>
    <time_frame>Around 8 weeks after treatment initiation</time_frame>
    <description>Patient preference compared with previous therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to treatment</measure>
    <time_frame>Around 8 weeks after treatment initiation</time_frame>
    <description>Number of days during the last 7 days with no treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment of Psoriasis</measure>
    <time_frame>Around 8 weeks after treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of treatment after completion of initial treatment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of treatment with Xamiol®gel on patients quality of life</measure>
    <time_frame>Around 8 weeks</time_frame>
    <description>Dermatology Life Quality Index (DLQI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall rate of treatment success</measure>
    <time_frame>Around 8 weeks</time_frame>
    <description>Clear or almost clear by Physician Psoriasis Global Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's willingness to pay</measure>
    <time_frame>12 months</time_frame>
    <description>Total consumption during study period in Russia where Xamiol®gel is not reimbursed</description>
  </secondary_outcome>
  <enrollment type="Actual">603</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol/betamethasone dipropionate gel</intervention_name>
    <description>Topical treatment of psoriasis plaques located on the body</description>
    <other_name>Xamiol®</other_name>
    <other_name>Daivobet®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with body psoriasis who (at their physician's discretion) are eligible
        to receive topical treatment with calcipotriol/betamethasone gel
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Psoriasis vulgaris on body

          -  Patients planned to receive topical treatment on the body with
             calcipotriol/betamethasone gel

          -  Written informed consent

        Exclusion Criteria:

          -  No or very mild symptoms of psoriasis vulgaris on the body at study start

          -  Any on-going treatments at study start with topical steroids, salicylic acid or its
             combination

          -  Other topical treatment for body psoriasis

          -  Pregnancy or planned pregnancy within treatment period

          -  Contraindications according to prescribing information.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dmitry Petrunin, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharmaceutical Products LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Municipal out-patient clinic 7</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2015</study_first_submitted>
  <study_first_submitted_qc>December 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2015</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

